Sionna Therapeutics announced that its SION-719 Phase 2a trial did not meet the key endpoint of reducing sweat chloride, a measure important in cystic fibrosis treatment. Following this announcement, the company's stock price dropped over 91%. Robbins Geller Rudman & Dowd LLP has launched an investigation into potential securities law violations related to this event. Investors who suffered losses may seek legal assistance as the case develops.
Comvita reported a net profit after tax (NPAT) of $7.7 million for the fiscal year ending June 30, 2026, marking a return to profitability. The company also significantly reduced its debt, normalized inventory levels, and restored positive cash flow....
Six months after the US and Israel launched combat operations in Iran, the conflict remains a stalemate with no clear resolution. The Trump administration has shifted from military action to economic pressure, including secondary sanctions, aiming to...
The U.S. SEC declared Evernorth Holdings' Form S-4 registration effective, allowing Armada Acquisition Corp. II shareholders to vote on the proposed merger on September 30, 2026. This merger would create a Nasdaq-listed company under the ticker XRPN,...
VictoryShares US Value Momentum ETF (ULVM) received a Hold rating because, despite its strong year-to-date performance, it faces long-term vulnerabilities. The ETF combines value and momentum investment strategies but leans towards low volatility, wh...
Bitcoin DeFi lending involves depositing BTC-related assets as collateral to borrow or supply liquidity, with returns from borrower interest or fees. Different lending models—pooled, isolated, stablecoin-backed, native BTC, and custodial—vary in risk...
